Market Overview
The plasma protein fraction (human) market is an integral part of the broader plasma fractionation and plasma protein therapeutics markets. Here, we delve into the key market dynamics and the financial trajectory of this biologic drug.
Global Market Size and Growth
The global plasma fraction market, which includes plasma protein fraction (human), was valued at approximately $32.75 billion in 2023. This market is projected to grow to $72.86 billion by 2034, with a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034[1].
Similarly, the global plasma protein therapeutics market, which encompasses plasma protein fraction, was valued at $26.5 billion in 2021 and is expected to reach $44.3 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031[3].
Drivers of Market Growth
Increasing Demand for Plasma-Derived Products
The rising demand for plasma-derived medicinal products (PDMPs) is a significant driver of the market. This demand is fueled by the need to treat various medical conditions, including immunodeficiencies, genetic defects, rabies, tetanus, shock, and trauma. The prevalence of global diseases such as immunodeficiencies and genetic disorders propels manufacturing companies to produce large quantities of high-quality medicine, thereby boosting the market[1].
Technological Advancements
Advancements in plasma fractionation technologies and the integration of recombinant DNA technology have enhanced the production and efficacy of plasma protein therapeutics. For instance, CSL's use of recombinant technology to generate improved molecules with extended half-lives has significantly benefited patients, making treatments more efficient and less frequent[2].
Expanding Applications
Plasma protein fraction (human) is used in a variety of clinical applications, including the treatment of coagulation factor deficiencies, reversing anticoagulant effects, and managing shock from plasma fluid loss. The expansion of these applications into new therapeutic areas continues to drive market growth[5].
Regional Market Dynamics
North America
North America dominates the plasma fraction market, largely due to the United States being a major exporter of plasma. The U.S. supplies about 70% of the world’s plasma, which is used for the production of PDMPs. This region is expected to continue its dominance due to increasing awareness and government initiatives promoting research activities for new plasma protein therapeutics[1][3].
Asia-Pacific
The Asia-Pacific region is expected to grow at the highest rate during the forecast period. This growth is attributed to the presence of pharmaceutical companies, increasing healthcare expenditure, and rising disposable incomes in countries like China and India. The growing prevalence of hemophilia and other bleeding disorders in this region also contributes to the market's expansion[3][4].
Financial Trajectory
Revenue Projections
The global plasma fractionation market is projected to grow from $35.21 billion in 2024 to $62.83 billion by 2032, exhibiting a CAGR of 7.5% during the forecast period. This significant growth indicates a robust financial trajectory for plasma protein fraction (human) and related products[4].
Cost and Sustainability
Despite the growth, the market faces challenges related to the high cost of plasma-derived products. The cost of plasma per liter has increased substantially, by 59.3% in Europe and 40.7% in the United States over the last five years. This increase directly impacts the sustainability of PDMP production, particularly during periods of high demand such as pandemics[1].
Market Segments
By Application
The hospital segment currently holds the largest market share due to the extensive use of plasma protein for patient treatment in hospitals. These proteins are crucial for recovering from burns, trauma, animal bites, shocks, major surgery, and various other medical conditions[1].
By Product Type
The coagulation factors segment is expected to grow at the fastest rate during the projected period. This growth is driven by the use of these factors in treating blood clotting diseases such as hemophilia and Von Willebrand’s disease[1].
Competitive Landscape
The market is characterized by the presence of several key players, including CSL, Grifols, and others. These companies are investing heavily in research and development to produce advanced and innovative plasma protein therapeutics. The competitive landscape is further shaped by the integration of new technologies and the expansion of product portfolios[2][3].
Challenges and Opportunities
High Cost and Shortages
The high cost of plasma-derived products and occasional shortages, especially during pandemics, pose significant challenges to the market. However, these challenges also present opportunities for innovation and cost reduction through technological advancements and increased donor participation[1].
Regulatory Environment
The regulatory environment plays a crucial role in the market. Products like plasma protein fraction (human) are subject to strict regulations, including those set by the FDA, which ensures the safety and efficacy of these biologics. Compliance with these regulations is essential for market growth[5].
Key Takeaways
- The global plasma fraction market, including plasma protein fraction (human), is projected to grow significantly, driven by increasing demand for PDMPs and technological advancements.
- North America dominates the market, but the Asia-Pacific region is expected to grow at the highest rate.
- The high cost of plasma-derived products and occasional shortages are key challenges, but they also drive innovation.
- The hospital segment and coagulation factors segment are critical areas of growth.
- Regulatory compliance is essential for the safe and effective production of plasma protein fraction (human).
Frequently Asked Questions
What is the current market size of the global plasma fraction market?
The global plasma fraction market was estimated at US$ 32.75 billion in 2023[1].
What is the projected growth rate of the plasma fraction market?
The market is projected to grow at a CAGR of 7.54% from 2024 to 2034[1].
Which region dominates the plasma fraction market?
North America dominates the plasma fraction market, with the United States being a major exporter of plasma[1].
What are the primary applications of plasma protein fraction (human)?
Plasma protein fraction (human) is used to treat coagulation factor deficiencies, reverse anticoagulant effects, and manage shock from plasma fluid loss[5].
What are the main challenges facing the plasma fraction market?
The main challenges include the high cost of plasma-derived products and occasional shortages, particularly during pandemics[1].
Sources
- Towards Healthcare: Plasma Fraction Market Size, Shares & 7.54% CAGR by 2034
- YouTube: CSL Documentary: Episode 3 - Plasma Proteins
- Allied Market Research: Plasma Protein Therapeutics Market Size, Share | Report - 2031
- Fortune Business Insights: Plasma Fractionation Market Size, Share | Global Report [2032]
- DrugBank: Plasma protein fraction (human) - DrugBank
